NEW YORK (GenomeWeb) – A team of researchers from Pfizer, the University of Glasgow, and Oxford BioDynamics have developed a new method to discern who will respond poorly to methotrexate, a drug sold by Pfizer that is commonly used to treat people with onset rheumatoid arthritis.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.